Immunome (IMNM) Operating Income: 2023-2025
Historic Operating Income for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$60.1 million.
- Immunome's Operating Income fell 19.03% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 26.23%. This contributed to the annual value of -$305.8 million for FY2024, which is 179.19% down from last year.
- Per Immunome's latest filing, its Operating Income stood at -$60.1 million for Q3 2025, which was down 29.39% from -$46.5 million recorded in Q2 2025.
- In the past 5 years, Immunome's Operating Income registered a high of -$4.5 million during Q1 2023, and its lowest value of -$132.3 million during Q1 2024.
- Its 3-year average for Operating Income is -$51.5 million, with a median of -$46.5 million in 2025.
- Its Operating Income has fluctuated over the past 5 years, first tumbled by 2,859.05% in 2024, then spiked by 66.26% in 2025.
- Immunome's Operating Income (Quarterly) stood at -$94.7 million in 2023, then grew by 12.34% to -$83.0 million in 2024, then fell by 19.03% to -$60.1 million in 2025.
- Its Operating Income was -$60.1 million in Q3 2025, compared to -$46.5 million in Q2 2025 and -$44.6 million in Q1 2025.